Hematological immune related adverse events after treatment with immune checkpoint inhibitors
2021 · European Journal of Cancer · 86 citations
https://doi.org/10.1016/j.ejca.2021.01.013
T
Tomohiro Enokida
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
139
Papers
1.3K
Citations
18
h-index
28
i10-index
Tomohiro Enokida is an academic researcher from National Cancer Center Hospital East. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Head and Neck Cancer Studies & Immunotherapy and Immune Responses. The author has an h-index of 18, co-authored 119 publications.
ORCID: 0000-0001-6505-7591Papers by this author
worksProton pump inhibitors and antibiotics adversely effect the efficacy of nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
2023 · European Journal of Cancer · 15 citations
https://doi.org/10.1016/j.ejca.2023.02.011
Giant extrachromosomal element “Inocle” potentially expands the adaptive capacity of the human oral microbiome
2025 · Nature Communications · 1 citations
https://doi.org/10.1038/s41467-025-62406-5
621P Phase II trial of encorafenib and binimetinib (E+B) in patients (pts) with BRAF-altered advanced solid tumors: Results of E+B cohort in the BELIEVE trial (NCCH1901)
2024 · Annals of Oncology · 0 citations
https://doi.org/10.1016/j.annonc.2024.08.688
A Case of Micro-medullary Thyroid Carcinoma Presenting as Cancer of Unknown Primary
2025 · Cureus · 0 citations
https://doi.org/10.7759/cureus.87085
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat